Overview

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

Status:
Completed

Trial end date:
2019-04-22

Target enrollment:

Participant gender:

Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia.

Phase:

Phase 3

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Treatments:

Atorvastatin
Atorvastatin Calcium